Abstract: Computational systems and methods are described for identifying new ?-helical antimicrobial peptides using a systemic consensus formula. Newly identified ?-helical antimicrobial peptides are tested experimentally and show potent microbiocidal activities.
Type:
Grant
Filed:
November 9, 2022
Date of Patent:
May 21, 2024
Assignee:
The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Abstract: The present disclosure relates generally to compositions and methods for treating, preventing, or slowing the rate of development of a disease or condition mediated by a nonsense mutation in the bone morphogenetic protein receptor type II (Bmpr2) in a subject in need thereof. The method entails administering to the subject a compound of the present disclosure, such as GJ103 and a salt thereof.
Type:
Grant
Filed:
February 25, 2020
Date of Patent:
August 23, 2022
Assignee:
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Abstract: Methods of modulating the interaction between ?-amyloid and ?7-nAChR are provided. Aspects of the methods include administering to the subject an effective amount of a naphthalene derivative active agent. Compositions and kits for practicing the subject methods are also provided. The methods, compositions and kits find use in treating a variety of applications, such as treating a subject for a neurodegenerative disease, e.g., Alzheimer's disease.
Type:
Grant
Filed:
April 5, 2018
Date of Patent:
July 12, 2022
Assignees:
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Collaborations Pharmaceuticals, Inc.
Inventors:
Aaron McMurtray, Julia Chung, Natalie Diaz, Sean Ekins
Abstract: Disclosed herein are methods and compositions useful for preventing or reducing corneal haze of opacification resulting from Limbal Stem Cell Deficiency (LSCD). The invention comprises a method of preventing or treating corneal opacification, comprising administering to a subject a sufficient amount of a proteasome modulator. The invention also comprises a method of preventing or treating corneal opacification, comprising administering to a subject a sufficient amount of a proteasome modulator. In addition, the invention comprises a method of administering to a subject suffering from corneal opacification with a sufficient amount of proteasome modulator, resulting in reduction of Keratin proteins in the cornea of the subject.
Type:
Grant
Filed:
November 11, 2016
Date of Patent:
August 11, 2020
Assignee:
The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Abstract: Peptides suitable for preparation of lung surfactants are described. Examples include one that include a first fragment comprising the amino acid sequence of XWLXRALIKRIQAZI (SEQ ID NO: 1) or a first amino acid sequence having at least 90% sequence identity to SEQ ID NO: 1 and a second fragment comprising the amino acid sequence of RZLPQLVXRLVLRXS (SEQ ID NO: 2) or a second amino acid sequence having at least 90% sequence identity to SEQ ID NO: 2, wherein X is any amino acid but at least one amino acid at the X positions is not cysteine, or Z is any amino acid but at least one amino acid at the Z positions is not methionine. Surfactants that contain such peptides, and related compositions, methods of preparing and using the compositions are also described.
Type:
Grant
Filed:
December 16, 2016
Date of Patent:
July 21, 2020
Assignee:
The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Inventors:
Frans J. Walther, Alan J. Waring, Larry M. Gordon